Antihypertensive and cardiovascular effects of combined blockade of renin-angiotensin system with ACE inhibitor and angiotensin II type 1 receptor blocker in hypertensive patients: A 24-week randomized controlled double-dummy trial
Abstract
Overview
Background. In this study the effects of 24 weeks losartan and ramipril treatment,
both alone and in combination, on blood pressure and left ventricular mass (LVM) and function,
have been evaluated in hypertensives.
Methods. 57 hypertensives with stage 1 and 2 essential hypertension were included. After 4
weeks run in, a randomized double-blind, 3 arm, double dummy, independent trial was used. All
patients were randomly allocated to 3 treatment arms consisting of losartan (50 mg/daily),
ramipril (5 mg/daily), and combined (losartan 50 mg/ramipril 5 mg/daily) for 24 weeks. LVM,
LVM/h2.7 and other echocardiographic measurements, BUN, creatinine and clearance and potassium
were determined after run in and 24 weeks.
Results. All groups were comparable for gender, age, BMI, BP and LVM. The prevalence of
baseline left ventricular hypertrophy (LVH) was not significantly different among 3 groups. At the
end of treatment, a significant (p<0.05) reduction in SBP, DBP, MBP, LVM and LVM/h2.7 were observed in all groups. The absolute and percent reduction in LVM/h2.7 were significantly higher in combined than losartan or ramipril groups and also in hypertensives with LVH. No significant change in absolute and percent reduction of SBP, DBP and MBP were found. Conclusions. These data indicate an additional cardioprotective effect of dual blockade of RAS in hypertensive patients with and without left ventricular hypertrophy. (Heart International 2006; 2: 39-48)
Keywords
Ace-inhibitors, Angiotensin II receptor blockers, Left ventricular geometry and function
Article Information
Correspondence
Rosario Scaglione, MD, Associate Professor of Medical Therapy, Via Lombardia, 9, 90144 Palermo – Italy, rosarioscaglione@yahoo.it
Acknowledgements
This study was supported in part by a project grant (60%)
from the University of Palermo, Italy.
Further Resources
Trending Topic
Hypertension is the leading modifiable risk factor for global cardiovascular disease, responsible for an estimated 10.8 million deaths and more than 200 million disability-adjusted life years annually.1 Despite the availability of effective pharmacological and lifestyle interventions, prevalence continues to rise, particularly in low- and middle-income countries (LMICs), where over three-quarters of all cases now occur.2 The condition’s […]
Hypertension is the leading modifiable risk factor for global cardiovascular disease, responsible for an estimated 10.8 million deaths and more than 200 million disability-adjusted life years annually.1Â Despite the availability of effective pharmacological and lifestyle interventions, prevalence continues to rise, particularly in ...
Hypertension affects over 1.4 billion adults worldwide and remains the leading modifiable risk factor for global cardiovascular (CV) morbidity and mortality. It is responsible for an estimated 10.8 million deaths annually and contributes significantly to the global burden of ischaemic heart disease, ...
Hypertension has been associated with increased cardiovascular morbidity and mortality, as well as with overall elevated all-cause mortality.1 Prevalence increases with age, affecting 28.5% of US individuals aged 20–44 years, 58.6% of those aged 45–64 years and 76.5% of those aged 65 years and older.2 In ...
Hypertension (HTN) is one of the largest contributors to cardiovascular (CV) morbidity and mortality in the USA and is estimated to affect 47% of the adult population or approximately 122 million adults older than 20 years of age.1Â Recent estimates suggest that over 40% ...
Atrial fibrillation (AF) is one of the most common arrhythmias. It affected 33.5 million people worldwide in 2010, a number that is expected to double by 2050.1Â AF prevalence increases with age, and approximately 25% of individuals aged 40 years or older will develop AF ...
Hypertension is a global health problem, with an estimated 1.13 billion individuals affected.1 Patients with hypertension, especially when resistant to conventional therapy, are at high risk of sequelae, e.g., ischaemic heart disease, haemorrhagic and ischaemic stroke, cardiac failure, peripheral vascular ...
...
...
...
...
...
...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
